R01CA255035

The impact of a changing health care delivery system on the quality of oncology care - project summary.

The cancer care delivery system frequently provides care that is not patient-centered, evidence-based, or accessible to vulnerable and underserved populations. Cancer care and outcomes are particularly poor for patients living in rural areas, areas with high poverty, racial/ethnic minorities, and patients with multimorbidity.

Recent advances such as genomic testing, targeted therapy, immunotherapy, and CAR T cell therapy have made oncology care more complex. Concurrently, there has been substantial integration and consolidation of the delivery of cancer care, and little is known about how consolidation impacts cancer care and outcomes.

As part of an Agency for Health Care Research and Quality initiative on health systems organization and performance, our team created a novel national database (Enhanced Database [EDB]). The EDB combines a wide variety of governmental and non-governmental proprietary sources to identify health systems as groups of commonly owned providers and contains microdata on physicians, physician practices, hospitals, and health systems.

We propose to leverage longitudinal data from the EDB to characterize the integration of cancer care over time, using these changes to understand effects on care delivery, including quality, diffusion of new therapies, utilization, and outcomes. We will study care for patients enrolled in fee-for-service Medicare and those enrolled in Medicaid.

In addition to studying claims-based measures of quality and utilization, we will link with clinical data about genetic testing and test results from Foundation Medicine, one of the country's largest providers of somatic genomic testing.

Specifically, we will:

1. Describe changes in integration and ownership of oncology care providers since 2010 and assess differences in these trends for providers serving large numbers of vulnerable or disadvantaged populations, including rural and urban poor patients, racial/ethnic minorities, and individuals with multimorbidity.

2. Leverage changes in the organization of care to assess the impact of integration and health system affiliation on quality of care, outcomes, utilization, and spending for patients with cancer. We will examine quality across multiple domains, including care coordination, guideline-recommended care, avoidance of low-value care, and patient experiences.

3. Understand the extent to which quality and value of cancer care delivered within vs. outside of integrated systems differs for various disadvantaged populations, including individuals living in rural and urban poor areas, racial/ethnic minorities, and individuals with multimorbidity.

Our study will provide oncology practitioners, payers, and policymakers valuable information to improve access, quality, and outcomes of oncology care. Our results will inform policies and practices related to the value of integration of oncology care, quality measurement, and design of alternative payment models.

President And Fellows Of Harvard College

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

Massachusetts United States

State-Wide

Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-19-056)

Amendment Since initial award the End Date has been extended from 11/30/25 to 11/30/26 and the total obligations have increased 465% from $730,012 to $4,126,391.